HDAC9 and neoplasm: To better understand how HDAC inhibitors fight against tumors at the cellular level, we first investigated the effectiveness of NBU-2 in inhibiting the proliferation of a broad panel of tumor cell lines, with a particular emphasis on hematological malignancies such as Jurkat, HL-60, CCRF-CEM, and U937.